ORBIMED CAPITAL LLC
CIK 1157524 · last filed 2026-04-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$111.35M
Companies
7
Total Filings
33
Lifetime Open-Market Net
$39.06M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRLD | Director | 1,126,126 | $4.64 | $5.23M | $65.00M | 3 | 2026-04-23 |
| SPRY | Director | 269,323 | $5.67 | $1.53M | -$3.26M | 1 | 2024-08-28 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 1,368,339 | $2.65 | $3.63M | $36.56M | 3 | 2023-05-08 |
| ARQT | Director | 3,534,537 | $28.42 | $100.45M | $43.84M | 3 | 2022-06-28 |
| PMVP | 10%+ Owner | 109,500 | $1.10 | $120.5K | -$41.06M | 1 | 2022-03-31 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 3,221,637 | $2.65 | $8.54M | -$1.85M | 1 | 2021-08-30 |
| ALEC | Director | 2,650,781 | $1.52 | $4.03M | -$60.17M | 3 | 2019-12-26 |
Recent Filings · Page 3 of 4
33 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-05-24 | PRLD | Buy (P) | +2,608,695 | $15.00M | EDGAR |
| 2023-05-08 | Kinnate Biopharma Inc. (KNTE) Delisted | Buy (P) | +10,226,524 | $28.60M | EDGAR |
| 2022-06-28 | ARQT | Sell (S) | −1,025,913 | -$21.86M | EDGAR |
| 2022-03-31 | PMVP | Sell (S) | −1,898,000 | -$41.06M | EDGAR |
| 2022-02-15 | Kinnate Biopharma Inc. (KNTE) Delisted | Buy (P) | +782,800 | $7.96M | EDGAR |
| 2021-08-30 | Repare Therapeutics Inc. (RPTX) Delisted | Sell (S) | −54,219 | -$1.85M | EDGAR |
| 2021-01-12 | PRLD | Buy (P) | — | $0 | EDGAR |
| 2020-12-09 | Kinnate Biopharma Inc. (KNTE) Delisted | Conv (C) | +12,391,716 | $0 | EDGAR |
| 2020-10-06 | ARQT | Buy (P) | +1,488,000 | $37.20M | EDGAR |
| 2020-02-04 | ARQT | Mixed | +14,021,550 | $28.50M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.